Efficacy of maintenance or consolidation therapy for multiple myeloma based on proteasome inhibitors: a meta-analysis.

Background: This study assessed the efficacy of proteasome inhibitors (PIs) in both maintenance and consolidation therapies for MM patients.

Methods: A comprehensive search across multiple databases was conducted, including PubMed, Science Direct, Google Scholar, CNKI, EMBASE, Web of Science, MEDLINE, Cochrane Library, and others, to identify randomized controlled trials published in both Chinese and English languages that examined the use of PIs in either consolidation or maintenance therapy for multiple myeloma. The effectiveness outcomes assessed included complete response (CR), very good partial response or better (≥ VGPR), partial response (PR), progression-free survival (PFS), and overall survival (OS).

Effects of mesenchymal stem cells from different sources on the biological functions of multiple myeloma cells.

Background: The therapeutic benefits of mesenchymal stromal cells (MSCs) are largely dependent on paracrine factors, but the supernatants of the different MSCs may have different effects on multiple myeloma (MM) cells. Therefore, this study compared supernatants of bone marrow-derived mesenchymal stromal cells (BM-MSCs) with umbilical cord wharton's jelly's mesenchymal stem cells (UC-WJ MSCs) in different states (non-senescent and replicative senescence) on the MM cells.

Methods: We extracted human BM-MSCs and UC-WJ MSCs in vitro and used HO to induce replicative senescence.

The Systematic Analysis of the Impact of China Water Improvement and Fluoride Reduction Project on Children.

Endemic fluorosis is a serious public health problem in China. In order to improve the quality of drinking water, China has implemented water rehabilitation and fluoride reduction projects, but their effect on children's health outcomes is unclear. This study reviewed relevant literature published in PubMed, Web of Science, Embase, CNKI, VIP, and WanFang from the date of establishment to October 2024.

Efficacy and safety of chimeric antigen receptor T cells targeting BCMA and GPRC5D in relapsed or refractory multiple myeloma.

Background: Clinical studies have demonstrated the high efficacy of using chimeric antigen receptor (CAR)-T cells targeting B-cell maturation antigen (BCMA) and orphan G protein-coupled receptor, class C group 5 member D (GPRC5D) to treat relapsed or refractory multiple myeloma (RRMM). In this study, we compared the efficacy and safety of BCMA CAR-T-cell therapy (BCMA CAR-T) and GPRC5D CAR T-cell therapy (GPRC5D CAR-T) in patients with RRMM.

Methods: We retrieved and included eligible clinical trials of BCMA or GPRC5D CAR-T for RRMM patients.

Efficacy and safety of lenalidomide in the treatment of B-cell non-Hodgkin lymphoma.

Background: The combination of rituximab and chemotherapy is a first-line treatment for patients with B-cell non-Hodgkin lymphoma. Lenalidomide is an immunomodulatory drug that has shown promising properties and activity in a variety of hematological malignancies. This study evaluated the efficacy and safety of lenalidomide-based regimens in the treatment of B-cell non-Hodgkin lymphoma.